Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on December 4, 2007
Japanese Journal of Clinical Oncology 2007 37(12):951-954; doi:10.1093/jjco/hym118
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/12/951    most recent
hym118v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Inaba, Y.
Right arrow Articles by Muro, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inaba, Y.
Right arrow Articles by Muro, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 Foundation for Promotion of Cancer Research

Central Venous Access Port-related Complications in Outpatient Chemotherapy for Colorectal Cancer

Yoshitaka Inaba1,, Hidekazu Yamaura1, Yozo Sato1, Mina Najima1, Hiroshi Shimamoto1, Hideyuki Nishiofuku1, Takashi Ura2 and Kei Muro2

1 Department of Diagnostic and Interventional Radiology
2 Department of Medical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

For reprints and all correspondence: Yoshitaka Inaba, Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, 1-1Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. E-mail: 105824{at}aichi-cc.jp

Received May 8, 2007; accepted August 2, 2007

Background: The current standard chemotherapy for advanced or metastatic colorectal cancer in Japan is FOLFOX or FOLFIRI therapy. Although both therapies include continuous infusion of 5-fluorouracil (5-FU), outpatient home chemotherapy is possible by placing a central venous access port (CV-port) and using a portable disposable pump. The port system has been placed more frequently since the approval of FOLFOX. Consequently, more complications involving ports and pumps have been encountered.

Methods: At our hospital, 232 patients with colorectal cancer underwent outpatient home chemotherapy by placing a CV-port and using a portable disposable pump for continuous infusion of 5-FU between 1998 and 2005. Incidence and contents of complications involving ports and pumps were investigated retrospectively.

Results: A total of 54 incidents of complications involving ports and pumps were identified in 3142 treatments (1.72%) from among 34 of the 232 patients (14.7%). In 2005, when FOLFOX was introduced, 31 incidents occurred in 1903 treatments (1.63%) for 19 of 149 patients (12.8%). Incidents involved port placement (n = 6), catheter and port system-related complications (n = 15), puncture needle-related complications (n = 3), skin complications related to tape fixation (n = 20) and pump-related complications (n = 10). In 10 patients (4.3%), system-related complications made therapy difficult to continue and system exchange was required.

Conclusions: Technical troubles involving ports and pumps occurred at a certain rate, and skin incision was required for system exchange in some cases. When performing outpatient chemotherapy using ports and pumps, thorough prior guidance and double-checking must be implemented, and proper countermeasures must be established.

Key Words: colorectal cancer • outpatient home chemotherapy • central venous access port • portable disposable pump • complication


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.